Home / Market News / $GLUE

$GLUE news and market catalysts

The 8 most recent market catalysts affecting $GLUE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 2 high impact 1 bullish 3 bearish Biotechnology
Nov 7, 2026 Corporate Catalyst Neutral Impact 55
Wells Fargo Maintains Buy Rating on Monte Rosa Therapeutics, Lowers Price Target
Wells Fargo analyst Derek Archila maintained a 'Buy' rating on Monte Rosa Therapeutics (GLUE), signaling continued confidence in the company's fundamentals. However, the simultaneo…
Oct 5, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Monte Rosa Therapeutics (GLUE) and maintained a $25 price target. Thi…
Oct 1, 2026 Corporate Catalyst Bullish Impact 85
GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?
Monte Rosa Therapeutics (GLUE) experienced a significant pre-market surge of over 20% as investors eagerly await expanded Phase 1 data for its experimental cardiovascular drug, MRT…
Oct 1, 2026 Corporate Catalyst Neutral Impact 65
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. initiating coverage on Monte Rosa Therapeutics with a 'Buy' rating and a $25 price target is a positive development for the company. Analyst coverage, especiall…
Aug 24, 2026 Corporate Catalyst Neutral Impact 65
Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations
Monte Rosa Therapeutics (GLUE) has dosed the first patient in its Phase 2 MODeFIRe-1 study for MRT-2359 in mCRPC. This is a positive development as it signifies progress in the cli…
Aug 7, 2026 Corporate Catalyst Bearish Impact 55
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
JP Morgan analyst Brian Cheng maintained an 'Overweight' rating on Monte Rosa Therapeutics, signaling continued confidence in the company's long-term prospects. However, the price …
Aug 6, 2026 Corporate Catalyst Bearish Impact 92
Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate
Monte Rosa Therapeutics (GLUE) reported Q2 earnings per share that missed analyst estimates by a substantial margin, indicating higher-than-anticipated losses. This is a negative s…
Aug 3, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27
Wedbush analyst Robert Driscoll maintained an 'Outperform' rating on Monte Rosa Therapeutics (GLUE) but lowered the price target from $37 to $27. This action signals that while the…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.